Alexion Pharma (ALXN) Tops Q1 EPS by 18c, Updates Guidance

Alexion Pharma (NASDAQ: ALXN) reported Q1 EPS of $1.68, $0.18 better than the analyst estimate of $1.50. Revenue for the quarter came in at $930.9 million versus the consensus estimate of $922.99 million.

GUIDANCE:

Alexion Pharma sees FY2018 EPS of $6.75-$6.90, versus the consensus of $6.86. Alexion Pharma sees FY2018 revenue of $3.925-3.985 million, versus the consensus of $3.98 million.

For earnings history and earnings-related data on Alexion Pharma (ALXN) click here.

You May Also Be Interested In

• Rivian reports record Q3 deliveries, beats estimates, shares rise
• Integra LifeSciences stock tumbles after cutting 2026 outlook
• Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'